ATE353916T1 - Chimärische natriuretische peptide - Google Patents

Chimärische natriuretische peptide

Info

Publication number
ATE353916T1
ATE353916T1 AT00988092T AT00988092T ATE353916T1 AT E353916 T1 ATE353916 T1 AT E353916T1 AT 00988092 T AT00988092 T AT 00988092T AT 00988092 T AT00988092 T AT 00988092T AT E353916 T1 ATE353916 T1 AT E353916T1
Authority
AT
Austria
Prior art keywords
natriuretic peptides
chimeric natriuretic
peptides
chimeric
natriuretics
Prior art date
Application number
AT00988092T
Other languages
English (en)
Inventor
John Burnett Jr
Ondrej Lisy
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Application granted granted Critical
Publication of ATE353916T1 publication Critical patent/ATE353916T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00988092T 1999-12-17 2000-12-15 Chimärische natriuretische peptide ATE353916T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/466,268 US6407211B1 (en) 1999-12-17 1999-12-17 Chimeric natriuretic peptides

Publications (1)

Publication Number Publication Date
ATE353916T1 true ATE353916T1 (de) 2007-03-15

Family

ID=23851133

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00988092T ATE353916T1 (de) 1999-12-17 2000-12-15 Chimärische natriuretische peptide

Country Status (11)

Country Link
US (4) US6407211B1 (de)
EP (1) EP1242452B1 (de)
JP (1) JP5031964B2 (de)
AT (1) ATE353916T1 (de)
AU (1) AU2433901A (de)
CA (1) CA2395585C (de)
DE (1) DE60033431T2 (de)
DK (1) DK1242452T3 (de)
ES (1) ES2282160T3 (de)
PT (1) PT1242452E (de)
WO (1) WO2001044284A2 (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5043900A (en) * 1999-05-24 2000-12-12 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
WO2003081246A1 (en) * 2002-03-18 2003-10-02 Scios Inc. Treatment of congestive heart failure with natriuretic peptide and a diuretic
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
AU2003270427A1 (en) * 2002-09-06 2004-03-29 University Of South Florida Cellular delivery of natriuretic peptides
US7655772B2 (en) 2002-09-06 2010-02-02 University Of South Florida Materials and methods for treatment of allergic diseases
BR0316560A (pt) * 2002-11-26 2005-10-04 Nobex Corp Conjugado de composto natriurético, formulação farmacêutica, método de tratar uma condição, método de preparação do conjugado de composto natriurético, conjugado de peptìdeo pró-polinatriurético modificado, análogo de peptìdeo natriurético, análogo de hbnp, composto, e, método de preparar um composto
WO2004097368A2 (en) * 2003-04-28 2004-11-11 Ciphergen Biosystems, Inc. Improved immunoassays
DK1638443T3 (da) 2003-06-20 2011-02-07 Mayo Foundation Isoformer af hjerne-natriuretisk peptid
GB2403533A (en) 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
US7445933B2 (en) * 2003-07-16 2008-11-04 Abbott Laboratories, Inc. Stable calibrators or controls for measuring human natriuretic peptides
US7291501B2 (en) * 2003-07-16 2007-11-06 Abbott Laboratories Stable compositions for measuring human natriuretic peptides
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CA2559853A1 (en) * 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
HUE039448T2 (hu) 2004-04-21 2018-12-28 Alexion Pharma Inc Csontba szállító konjugátumok és alkalmazási módszerük a fehérjék csontba juttatására
ATE496060T1 (de) * 2004-07-15 2011-02-15 Univ Queensland Proteinartige verbindungen und anwendungen davon
AT500800B1 (de) * 2004-09-08 2008-07-15 Biomedica Medizinprodukte Gmbh Verfahren zur bestimmung von probnp
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
WO2007022123A2 (en) * 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
WO2006086769A2 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
PT1865976E (pt) 2005-04-07 2012-08-03 Cardiopep Pharma Gmbh Utilização de péptido natriurético para tratar a insuficiência cardíaca
WO2007035600A2 (en) * 2005-09-16 2007-03-29 Mayo Foundation For Education And Research Natriuretic activities
AU2007233123A1 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
CA2647143A1 (en) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
WO2007127487A2 (en) * 2006-04-28 2007-11-08 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
JP5702930B2 (ja) 2006-08-08 2015-04-15 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 利尿ポリペプチドおよびナトリウム利尿ポリペプチド
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2008031045A2 (en) 2006-09-08 2008-03-13 Mayo Foundation For Medical Education And Research Aquaretic and natriuretic polypeptides lacking vasodilatory activity
WO2008092019A1 (en) * 2007-01-25 2008-07-31 Mayo Foundation For Medical Education And Research Fgf-23 polypeptides
DK2171053T3 (da) * 2007-07-20 2014-07-28 Mayo Foundation Natriuretiske polypeptider
WO2009036448A2 (en) 2007-09-15 2009-03-19 Mayo Foundation For Medical Education And Research Natriuretic peptide receptor-c agonists
US20090110638A1 (en) * 2007-10-24 2009-04-30 California Institute Of Technology Methods using the grueneberg ganglion chemosensory system
US8377884B2 (en) * 2007-11-21 2013-02-19 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptides
WO2009086126A2 (en) * 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US9482677B2 (en) 2008-02-27 2016-11-01 Scios Inc. Method, composition and device for sampling natriuretic peptides in a biological fluid
JP2011522824A (ja) * 2008-06-06 2011-08-04 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ キメラナトリウム利尿ポリペプチドおよび心臓リモデリングを阻害するための方法
WO2010033216A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of nesiritide peptides
US8680263B2 (en) * 2008-09-19 2014-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
WO2010048308A2 (en) * 2008-10-24 2010-04-29 Deborah Dickey Natriuretic polypeptides
US8455438B2 (en) 2008-12-29 2013-06-04 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
US20120053123A1 (en) * 2009-05-05 2012-03-01 Mayo Foundation For Medical Education And Research Natriuretic polypeptides having mutations within their disulfide rings
PE20120792A1 (es) 2009-05-20 2012-07-27 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
WO2011005939A2 (en) 2009-07-09 2011-01-13 Mayo Foundation For Medical Education And Research Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
RU2572694C2 (ru) 2009-07-23 2016-01-20 ИГИСУ Ко., Лтд. Композиция кожного препарата для наружного применения
BR112012004058A2 (pt) 2009-08-27 2021-08-17 Kyoko Endo preparação terapêutica para rinite
DE102010032482A1 (de) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe zur Beeinflussung der natriuretischen Peptid-Rezeptoren A und B und deren Verwendung
WO2012013597A1 (de) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe und deren verwendung zur beeinflussung natriuretischer peptidrezeptoren
US8778699B2 (en) 2010-08-04 2014-07-15 Idexx Laboratories, Inc. Detection of degradation products of canine NT-proBNP
WO2012058585A2 (en) 2010-10-29 2012-05-03 Nile Therapeutics, Inc. Methods of treatment with natriuretic peptides
EP2658979B1 (de) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Zusammensetzungen mit natriuretischen peptiden und verwendungsverfahren dafür
ES2647680T3 (es) 2011-01-21 2017-12-26 Igisu Co., Ltd. Fármaco terapéutico para la alopecia
US20120277155A1 (en) 2011-02-25 2012-11-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
AU2012262154B2 (en) 2011-05-31 2016-08-04 Idexx Laboratories, Inc. Detection of degradation products of feline NT-proBNP
CN103906761B (zh) 2011-08-30 2016-12-21 梅约医学教育与研究基金会 利钠多肽
EP2750697A4 (de) 2011-09-02 2015-03-25 Medtronic Inc Chimäre natriuretische peptidzusammensetzungen und verfahren zu ihrer herstellung
KR20140084201A (ko) 2011-10-19 2014-07-04 알렉시온 파마 홀딩 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법
WO2013070741A1 (en) * 2011-11-11 2013-05-16 Mayo Foundation For Medical Education And Research Methods and materials for regulating natriuretic polypeptide function
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
EP2833957A4 (de) * 2012-04-02 2016-03-09 Capricor Therapeutics Inc Therapie für nierenerkrankungen und/oder herzinsuffizienz durch intradermale infusion
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US8835601B2 (en) * 2012-12-21 2014-09-16 Mayo Foundation For Medical Education And Research Natriuretic polypeptide delivery systems
NZ710246A (en) * 2013-01-25 2016-11-25 Cardiorentis Ltd Methods of treating cardiovasular indications
CN103159847B (zh) * 2013-04-12 2014-05-28 叶亮 一种利钠肽及其基因与用途
WO2014209229A1 (en) * 2013-06-25 2014-12-31 National University Of Singapore Vasodilation peptides and uses thereof
US9863900B2 (en) 2014-01-28 2018-01-09 Transtech Systems, Inc. Planar sensor array for non-destructive evaluation of material using electromagnetic impedance
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
US10161893B2 (en) 2014-08-19 2018-12-25 Transtech Systems, Inc. Characterization of material under test (MUT) with electromagnetic impedance spectroscopy
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
AU2016272282A1 (en) 2015-05-29 2018-01-25 Igisu Co., Ltd. Cyclic peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide
KR102644116B1 (ko) 2015-08-17 2024-03-05 알렉시온 파마슈티칼스, 인코포레이티드 알칼린 포스파타제의 제조
EP3355904A4 (de) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifizierung wirksamer dosierungsschemata für gewebeunspezifische alkalische phosphatase-enzymersatztherapie von hypophosphatasie
EP3368062A4 (de) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von craniosynostose bei einem patienten
EP3426286A4 (de) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von hypophosphatasie bei kindern
MX2018011833A (es) 2016-04-01 2019-02-13 Alexion Pharma Inc Tratamiento para la debilidad muscular con fosfatasas alcalinas.
EP3436020A4 (de) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von hypophosphatasie bei jugendlichen und erwachsenen
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
SG11201901226RA (en) * 2016-08-18 2019-03-28 Nat Univ Singapore Peptides with vasodilatory and/or diuretic functions
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
AU2018243320A1 (en) 2017-03-31 2019-10-10 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862925A (en) * 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) * 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (de) * 1974-03-08 1982-06-04
US4105602A (en) * 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
US4161521A (en) * 1975-08-08 1979-07-17 Merck & Co., Inc. Somatostatin analogs
US4051842A (en) * 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) * 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4383529A (en) * 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4757048A (en) * 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US4804650A (en) * 1986-10-28 1989-02-14 Biotechnology Research Associates, J.V. Analogs of atrial natriuretic peptides
US5691310A (en) * 1987-09-29 1997-11-25 Vesely; David L. Methods of treatment using proANF peptides
US4935492A (en) * 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides
US5047397A (en) * 1988-08-26 1991-09-10 California Biotechnology Inc. Linear analogs of atrial natriuretic peptides
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5202239A (en) 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
CA2113990A1 (en) 1991-07-26 1993-02-18 Frederick L. Moolten Cancer therapy utilizing malignant cells
AU6360394A (en) 1993-03-03 1994-09-26 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
DK0914344T3 (da) 1996-03-04 2005-08-29 Scios Inc Assay og reagenser til kvantificering af hBNP
US5848956A (en) * 1997-03-18 1998-12-15 Grettner; Norman L. Multi-purpose lat sling
WO1999012576A2 (en) * 1997-09-11 1999-03-18 Musc Foundation For Research Development Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy
AU5043900A (en) * 1999-05-24 2000-12-12 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides

Also Published As

Publication number Publication date
US20090170756A1 (en) 2009-07-02
AU2433901A (en) 2001-06-25
WO2001044284A2 (en) 2001-06-21
US6407211B1 (en) 2002-06-18
JP5031964B2 (ja) 2012-09-26
EP1242452A2 (de) 2002-09-25
DE60033431D1 (de) 2007-03-29
ES2282160T3 (es) 2007-10-16
US20050059600A1 (en) 2005-03-17
US6818619B2 (en) 2004-11-16
US7964564B2 (en) 2011-06-21
WO2001044284A3 (en) 2002-01-31
CA2395585C (en) 2014-09-09
EP1242452B1 (de) 2007-02-14
US20020082219A1 (en) 2002-06-27
US20030069186A1 (en) 2003-04-10
CA2395585A1 (en) 2001-06-21
US7384917B2 (en) 2008-06-10
JP2003517005A (ja) 2003-05-20
PT1242452E (pt) 2007-05-31
DK1242452T3 (da) 2007-06-11
DE60033431T2 (de) 2007-11-29

Similar Documents

Publication Publication Date Title
DE60033431D1 (de) Chimärische natriuretische peptide
GEP20105118B (en) Anti-vegf antibodies
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
MXPA03007319A (es) Anticuerpos contra egfr modificados, con inmunogenicidad reducida.
WO2001053312A8 (en) Novel nucleic acids and polypeptides
DE69534778D1 (en) Cathepsin-02-protease
WO2001053455A3 (en) Novel nucleic acids and polypeptides
WO2001075067A3 (en) Novel nucleic acids and polypeptides
WO2001057188A3 (en) Novel nucleic acids and polypeptides
WO2001057190A3 (en) Novel nucleic acids and polypeptides
WO2002022660A3 (en) Novel nucleic acids and polypeptides
WO2001066689A3 (en) Novel nucleic acids and polypeptides
WO2002031111A3 (en) Novel nucleic acids and polypeptides
WO2001088088A3 (en) Novel nucleic acids and polypeptides
IL195338A0 (en) Optimized fc variants and methods for their generation
WO2002059260A3 (en) Nucleic acids and polypeptides
EP1162264A3 (de) Chimärer Hormonrezeptor
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
WO2004087874A3 (en) Novel nucleic acids and polypeptides
ITRM990803A0 (it) Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
WO2002018424A3 (en) Nucleic acids and polypeptides
WO2001079449A3 (en) Novel nucleic acids and polypeptides
DE69938130D1 (de) Neue peptide
BR0008187A (pt) Controle biológico de nematódeos
WO2002044340A3 (en) Novel nucleic acids and polypeptides

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1242452

Country of ref document: EP